PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of isrnoticesInternational Scholarly Research Notices
 
Int Sch Res Notices. 2014; 2014: 186207.
Published online 2014 October 29. doi:  10.1155/2014/186207
PMCID: PMC4897426

An Efficient and Facile Synthesis of 1,2,4-Aryl Triazoles and 4-Thiazolidinones Bearing 6-Fluorochroman Nucleus

Abstract

A new generation of chroman bearing heterocyclic five membered ring such as 1,2,4-triazoles and thiazolidinones was designed and synthesized. New chroman based nucleus 5-(6-fluorochroman-2-yl)-4-aryl-4H-1,2,4-triazole-3-thiol and 6-fluorochroman-N-(4-oxo-2-arylthiazolidinin-3-yl) chroman-2-carboxamides were synthesized. Aryl triazole compounds 4a–4j were synthesized from 6-fluorochroman-2-carbohydrazide 2 on reaction with base in methanol and CS2 followed by reaction with substituted aniline. Thiazolidinone compounds 5a–5j were synthesized from 6-fluorochroman-2-carbohydrazide 2 on reaction with substituted aryl aldehyde and thioglycolic acid.

1. Introduction

The design and synthesis of hybrid molecules encompassing two pharmacophores in one molecular scaffold is a well-established approach to the synthesis of more potent drugs with dual activity. With this aspect, 6-fluorochroman-2-carboxylic acid derivatives in connection with thiazolidinone and 1, 2, 4-triazoles were found as a promising target for the current research project. 1, 2, 4-Triazoles and 4-thiazolidinones are the broadly investigated molecules. They have proved to be the most useful framework for biological activities among nitrogen containing five membered heterocycles. Amongst the diverse classes of heterocyclic compounds chroman, a class of oxygen containing heterocycle forms an important part of many pharmacologically active compounds. For example, the chroman ring is a constituent of various bioactive compounds that are sodium channel blocker [1], 5HT1A inhibitor [2], and so forth. Commercially available antihypertensive drugs of chroman repinotan [3], robalzotan [4], and specifically 6-fluorochroman nebivolol [5] are well known. Hence, the synthesis of 6-fluorochroman derivatives is currently of significant interest in organic synthesis.

Aryl triazoles comprise various heterocyclic compounds possessing promising biological activity and are found as potential antimicrobial [6, 7] and adenosine A2A receptor antagonist [8]. According to the green chemistry approach there are many solvent free reactions of 1, 2, 4-aryl triazoles that have been reported [9, 10].

4-Thiazolidinones have been widely explored for their applications in the field of medicine and agriculture [11]. They are also known as promising antimicrobial [12], antiinflammatory [13, 14], antimalerial [15], anticancer [16], tuberculostatic [17], and antiviral agents [18]. Several one-pot multicomponent syntheses of 4-thiazolidinone have been reported [1921].

2. Result and Discussion

The syntheses of triazole and thiazolidinone derivatives have been previously reported by many researchers, and they normally required additional additives and long reaction time. So in this paper, we described an efficient and safe procedure for the synthesis of 4-aryl triazole containing chroman nucleus, using 6-fluorochroman-2-carboxylic acid. 6-Fluorochroman-2-carboxylic acid on esterification with methanol in the presence of concentrated H2SO4 at room temperature gave compound 1 (Scheme 1) with good yield which on reaction with hydrazine hydrate (99%) gave compound 2. Compound 2 on reaction with carbon disulphide in the presence of KOH in methanol at RT afforded compound 3. This on further reaction with substituted aniline without use of any solvent in fused condition yielded compounds 4a–4j (Scheme 1). 1H and 13C NMR spectra of the products clearly indicated the formation of triazoles 4a–4j in 75–95% yields (Table 1). The formation of thiol group –SH was identified by a sharp singlet at around δ = 11.43 ppm. By the 13C NMR spectrum also supported the presence of –SH group from the deshielding value of carbon attached to –SH group at δ 168.71 ppm.

Scheme 1
Reaction scheme for the synthesis of 4a–4j.
Table 1
Physical data for 4a4j.

Here we introduce the one-pot synthesis of thiazolidinone from hydrazide (Scheme 2) with thioglycolic acid, substituted aryl aldehydes in toluene using a Dean-Stark assembly to synthesized compounds 5a–5j (Scheme 2). 1H and 13C NMR spectra of the products clearly indicated the formation of 4-thiazolidinone 5a–5j in 71–95% yields (Table 2). The formation of –NH group was identified by a sharp singlet at around δ 10.46–10.43 ppm, which is further supported by D2O exchange. 13C NMR spectrum also supported the presence of amide group from the deshielding value of carbon attached to –CONH group at δ 169.3 ppm and carbonyl group (part of a five member ring) at δ 169.47 ppm.

Scheme 2
Reaction scheme for the synthesis of 5a–5j.
Table 2
Physical data for 5a5j.

3. Conclusion

In summary, an efficient protocol for the synthesis of new 1, 2, 4-aryl triazoles and 4-thiazolidinones has been described. Herein, we are reporting the solvent free protocol for the synthesis of N-substituted 1, 2, 4-aryl triazoles (4a–4j) from potassium salt (3) . In literature, the synthesis of 4-thiazolidinones was carried out via 2 steps, but, to avoid multisteps and to make it more viable, we have developed a single-step reaction for the synthesis of 4-thiazolidinones (5a-5j) from hydrazide (2) .

4. Experimental

Melting points were determined in open capillary tubes and are uncorrected. Formation of the compounds was checked by TLC on silica gel-G plates of 0.5 mm thickness. IR spectra were recorded on Shimadzu FT-IR-8400 instrument using DRS (diffusive reflectance system) method. Mass spectra were recorded on Shimadzu GC-MS system (model QP-2010) using direct inlet probe technique. 1H NMR and 13C NMR were determined in CDCl3 and DMSO-d6 on a Bruker AC 400 MHz and 100 MHz spectrometer. Elemental analysis of all the synthesized compounds was carried out on Euro EA 3000 elemental analyzer and the results are in agreement with the structures assigned.

4.1. General Procedure for the Synthesis of Functionalized 1, 2, 4-Aryl Triazoles  (4a–4j)

To a stirred solution of 6-fluorochroman-2-carboxylic acid (0.01 mol) in methanol at room temperature, concentrated H2SO4 (0.01 mol) was added and reaction mixture was allowed to stir at RT for 10 hours. After completion of the reaction, solvent was evaporated and the resulting mass was poured on to ice, neutralized with saturated sodium bicarbonate solution. Separated solid precipitate was filtered, washed with water, and dried to afford methyl 6-fluorochroman-2-carboxylate 1.

Compound 1 (0.01 mol) in absolute ethanol was taken into the RBF and cooled at (−5)°C. To the previously cooled solution hydrazine hydrate (99%, 0.08 mol) was added and reaction mixture was allowed to stir at 0–(−5)°C for 10 hours. After the completion of reaction separated solid residues were filtered, washed with cold ethanol, and dried to afford 6-fluorochroman-2-carbohydrazide 2, yield: 2.0 g (98%).

To a mixture of compound 2 (0.1 mol) and potassium hydroxide (0.15 mol) in methanol carbon disulphide (0.15 mol) was added dropwise. Reaction mass was allowed to stir at RT for 22–24 hours. After completion of reaction the obtained solid was filtered, washed with diethyl ether, and dried to afford compound 3. There is no need to purify the salt for further reaction.

An equimolar mixture of potassium 2-[(6-fluorochroman-2-yl) carbonyl] hydrazine carbodithioate 3 (0.01 mol) and substituted aniline (0.01 mol) was taken in RBF and heated at 140–150°C for 12–15 hours until the evolution of H2S gas ceased. After completion of reaction solid residue was dissolved in DMF, treated with dilute HCl, and poured on crushed ice. The product was isolated and crystallized from ethanol to give compounds 4a–4j as analytical pure product.

4.1.1. 5-(6-Fluorochroman-2-yl)-4-(p-tolyl)-4H-1, 2, 4-triazole-3-thiol (4a)

Yield 89%, mp 170–172°C; IR (DRS): 3076(Ar, C–H str.), 2924(C–H str.), 2573(–SH str.), 1735(C=O str.), 1087(C–N str.), 1041(C–O–C str.) cm−1; 1H NMR (400 MHz, CDCl3): δ ppm 2.02–2.44(m, 5H, 2CH, 3CH), 2.65–2.96(m, 2H, 2CH), 4.83–4.90(dd, J = 12.6 Hz, 6 Hz, 1H, CH), 6.60–6.64(m, 1H, ArH), 6.73–6.76(m, 2H, ArH), 7.05–7.49(m, 4H, ArH), 11.43(s, 1H, SH). 13C NMR (100 MHz, CDCl3): δ ppm 20.3(CH3), 26.27(CH2), 28.87(CH2), 85.3(CH), 108.52(CH), 112.98(CH), 116.81(CH), 119.54(CH), 129.2(C), 131.16(C), 133.09(CH), 136.12(C), 139.69(C), 155.8(C), 158.29(C), 173.99(C). MS: m/z = 341 [M]+; Anal. Calcd for C18H16FN3OS: C, 63.32; H, 4.72; N, 12.31. Found: C, 63.23; H, 4.41; N, 12.28%.

4.1.2. 4-(3-Chlorophenyl)-5-(6-fluorochroman-2-yl)-4H-1, 2, 4-triazole-3-thiol (4b)

Yield 86%, mp 205–207°C; IR (DRS): 3066(Ar, C–H str.), 2914(C–H str.), 2850(C–H str.), 2533(–SH str.), 1558(Ar, C=C bend.), 1375(C–H ben), 800(C–Cl str.), 1087(C–N str.), 1041(C–O–C str.) cm−1; 1H NMR (400 MHz, DMSO-d6): δ ppm 2.27–2.30(m, 2H, 2CH), 2.82–2.95(m, 2H, 2CH), 4.92–4.95(dd, J = 6.12 Hz, 12 Hz, 1H, CH), 6.50–6.54(m, 1H, ArH), 6.75–6.79(m, 2H, ArH), 7.41–7.43(m, 1H, ArH), 7.53–7.55(m, 3H, ArH), 14.0(s, 1H, SH). 13C NMR (100 MHz, DMSO-d6): δ ppm 25.27(CH2), 28.27(CH2), 85.3(CH), 112.98(CH), 116.81(CH), 120.08(CH), 122.3(CH), 125.68(CH), 129.2(C), 133.41(CH), 138.88(C), 139.69(C), 142.37(C), 155.8(C), 158.29(C), 173.99(C) MS: m/z = 361 [M]+; Anal. Calcd for C17H13ClFN3OS: C, 56.43; H, 3.62; N, 11.61. Found: C, 56.18; H, 3.49; N, 11.59%.

4.1.3. 5-(6-Fluorochroman-2-yl)-4-(4-fluorophenyl)-4H-1, 2, 4-triazole-3-thiol (4c)

Yield 78%, mp 188–190°C; IR (DRS): 3030(Ar, C–H str.), 2558(–SH str.), 1581(–C=C–, str.), 1225(C–O–C str.) cm−1; 1H NMR (400 MHz, CDCl3): δ ppm 2.21–2.46(m, 2H, 2CH), 2.75–2.85(m, 2H, 2CH), 4.88–4.93(dd, J = 12.6 Hz, 6 Hz, 1H, CH), 6.51–6.55(m, 1H, ArH), 6.77–6.81(m, 2H, ArH), 7.53–7.57(m, 3H, ArH), 13.05(s, 1H, SH). 13C NMR (100 MHz, CDCl3): 26.27(CH2), 28.87(CH2), 85.3(CH), 108.52(CH), 112.98(CH), 116.81(CH), 118.6(CH), 122.97(CH), 129.2(C), 133.7(C), 139.69(C), 155.8(C), 158.29(C), 160.51(C), 173.99(C). MS: m/z = 345 [M]+; Anal. Calcd for C17H13F2N3OS: C, 59.12; H, 3.79; N, 12.17. Found: C, 59.02; H, 3.53; N, 12.01%.

4.1.4. 4-(2, 5-Dimethylphenyl)-5-(6-fluorochroman-2-yl)-4H-1, 2, 4-triazole-3-thiol (4d)

Yield 95%, mp 123–125°C; IR (DRS): 3074(Ar, C–H str.), 2984(C–H str.), 1645(–C=C–, str.), 1468(C–H bending) cm−1; 1H NMR (400 MHz, CDCl3): δ ppm 1.92(s, 6H, 3CH, 3CH), 2.21–2.46(m, 2H, 2CH), 2.75–2.85(m, 2H, 2CH), 4.85–4.92(dd, J = 12.6 Hz, 6 Hz, 1H, CH), 6.72–6.95(m, 3H, ArH), 7.29–7.43(m, 3H, ArH), 13.05(s, 1H, SH). 13C NMR (100 MHz, CDCl3): δ ppm 17.98(CH3), 26.87(CH2), 28.87(CH2), 30.2(CH3), 85.3(CH), 108.52(CH), 116.81(CH), 118.6(CH), 112.98(CH), 124.19(CH), 132.61(CH), 134.95(C), 138.13(C), 140.75(C), 146.2(C), 155.8(C), 158.29(C), 175.05(C). MS: m/z = 355 [M]+; Anal. Calcd for C19H18FN3OS: C, 64.21; H, 5.10; N, 11.82. Found: C, 64.16; H, 4.93; N, 11.78%.

4.1.5. 4-(3, 4-Dimethylphenyl)-5-(6-fluorochroman-2-yl)-4H-1, 2, 4-triazole-3-thiol (4e)

Yield 84%, mp 163–165°C; IR (DRS): 3081(Ar, C–H str.), 2975(C–H str.), 2575(–SH str.), 1641(C–H bending), 1579(–C=C–, str.), 1142(C–F str.) cm−1; 1H NMR (400 MHz, CDCl3): δ ppm 2.34(s, 6H, 3CH, 3CH), 2.21–2.46(m, 2H, 2CH), 2.75–2.85(m, 2H, 2CH), 4.85–4.92(dd, J = 12.6 Hz, 6 Hz, 1H, CH), 6.72–6.95(m, 3H, ArH), 7.29–7.43(m, 3H, ArH), 13.05(s, 1H, SH). 13C NMR (100 MHz, CDCl3): δ ppm 19.0(CH3), 20.01(CH3), 26.27(CH2), 28.87(CH2), 85.3(CH), 112.98(CH), 116.81(CH), 117.91(CH), 124.04(CH), 129.2(C), 132.85(C), 133.52(C), 139.69(C), 141.78(C), 143.79(C), 155.8(C), 158.29(C), 173.998(C). MS: m/z = 355 [M]+; Anal. Calcd for C19H18FN3OS: C, 64.21; H, 5.10; N, 11.82. Found: C, 64.09; H, 5.03; N, 11.50%.

4.1.6. 5-(6-Fluorochroman-2-yl)-4-(2-fluorophenyl)-4H-1, 2, 4-triazole-3-thiol (4f)

Yield 79%, mp 108–110°C; IR (DRS): 3080(Ar, C–H str.), 2983(C–H str.), 2561(–SH str.), 1629(C–H bending), 1572(C–H bending), 1525(–C=C–, str.) 1196(C–O–C str.) cm−1; 1H NMR (400 MHz, CDCl3): δ ppm 2.34(s, 6H, 3CH, 3CH), 2.21–2.46(m, 2H, 2CH), 2.75–2.85(m, 2H, 2CH), 4.90–4.97(dd, J = 12.6 Hz, 6 Hz, 1H, CH), 6.72–6.95(m, 3H, ArH), 7.24–7.75(m, 3H, ArH), 13.05(s, 1H, SH). 13C NMR (100 MHz, CDCl3): δ ppm 26.27(CH2), 28.87(CH2), 85.3(CH), 108.52(CH), 112.98(CH), 116.81(CH), 119.7(C), 119.58(CH), 129.2(C), 129.95(CH), 130.09(CH), 130.97(CH), 139.69(C), 155.8(C), 158.29(C), 162.56(C), 173.99(C). MS: m/z = 345 [M]+; Anal. Calcd for C17H13F2N3OS: C, 59.12; H, 3.79; N, 12.17. Found: C, 58.96; H, 3.67; N, 12.06%.

4.1.7. 4-(2-Chlorophenyl)-5-(6-fluorochroman-2-yl)-4H-1, 2, 4-triazole-3-thiol (4g)

Yield 76%, mp 192–194°C; IR (DRS): 3077(Ar, C–H str.), 2978(C–H str.), 2563(–SH str.), 1563(–C=C–, str.), 1464(H–C–H bend), 1310(C–O str.), 870(C–Cl str.) cm−1; 1H NMR (400 MHz, CDCl3): δ ppm 2.34(s, 6H, 3CH, 3CH), 2.21–2.46(m, 2H, 2CH), 2.75–2.85(m, 2H, 2CH), 4.90–4.97(dd, J = 12.6 Hz, 6 Hz, 1H, CH), 6.72–6.95(m, 3H, ArH), 7.39–7.50(m, 3H, ArH), 13.05(s, 1H, SH). 13C NMR (100 MHz, CDCl3): δ ppm 26.27(CH2), 28.87(CH2), 85.3(CH), 108.52(CH), 112.98(CH), 116.81(CH), 127.83(CH), 126.39(C), 128.04(CH), 129.2(C), 131.85(CH), 132.57(CH), 140.8(C), 142.53(C), 155.8(C), 158.29(C), 175.1(C). MS: m/z = 361 [M]+; Anal. Calcd C17H13ClFN3OS: C, 56.43; H, 3.62; N, 11.61. Found: C, 55.97; H, 3.55; N, 11.59%.

4.1.8. 4-(3-Chloro-4-fluorophenyl)-5-(6-fluorochroman-2-yl)-4H-1,2,4-triazole-3-thiol (4h)

Yield 87%, mp 139–141°C; IR (DRS): 3075(Ar, C–H str.), 2553(–SH str.), 1581(–C=C–, str.), 1423(H–C–H bend), 1281(C–O str.), 870(C–Cl str.) cm−1; 1H NMR (400 MHz, DMSO-d6): δ ppm 2.34(s, 6H, 3CH, 3CH), 2.21–2.46(m, 2H, 2CH), 2.75–2.85(m, 2H, 2CH), 4.90–4.97(dd, J = 12.6 Hz, 6 Hz, 1H, CH), 6.72–6.95(m, 3H, ArH), 7.18–7.79(m, 3H, ArH), 13.05(s, 1H, SH). 13C NMR (100 MHz, DMSO-d6): δ ppm 26.27(CH2), 28.87(CH2), 85.3(CH), 108.52(CH), 112.98(CH), 116.81(CH), 120.08(CH), 121.91(CH), 124.85(C), 125.71(CH), 129.2(C), 139.69(C), 141.09(C), 155.8(C), 156.41(C), 158.29(C), 173.99(C). MS: m/z = 379 [M]+; Anal. Calcd for C17H12ClF2N3OS: C, 53.76; H, 3.18; N, 11.06. Found: C, 53.69; H, 3.07; N, 10.90%.

4.1.9. 5-(6-Fluorochroman-2-yl)-4-(2-methoxyphenyl)-4H-1, 2, 4-triazole-3-thiol (4i)

Yield 90%, mp 251–253°C; IR (DRS): 3075(Ar, C–H str.), 2553(–SH str.), 1581(–C=C–, str.), 1423(H–C–H bend), 1281(C–O str.), 870(C–Cl str.), 1080(C–F str.) cm−1; 1H NMR (400 MHz, DMSO-d6): δ ppm 2.34(s, 6H, 3CH, 3CH), 2.21–2.46(m, 2H, 2CH), 2.75–2.85(m, 2H, 2CH), 3.83(s, 3H, OCH3), 4.90–4.97(dd, J = 12.6 Hz, 6 Hz, 1H, CH), 6.72–6.95(m, 3H, ArH), 6.99–7.51(m, 4H, ArH), 13.05(s, 1H, SH). 13C NMR (100 MHz, DMSO-d6): δ ppm 26.27(CH2), 28.87(CH2), 56.32(CH3), 85.3(CH), 108.52(CH), 112.98(CH), 115.51(CH), 116.81(CH), 120.83(CH), 123.69(CH), 129.2(C), 131.19(CH), 134.73(C), 139.24(C), 155.8(C), 157.76(C), 158.29(C), 173.54(C). MS: m/z = 357 [M]+; Anal. Calcd for C18H16FN3O2S: C, 60.49; H, 4.51; N, 11.76. Found: C, 60.39; H, 4.29; N, 11.37%.

4.1.10. 4-(2, 5-Difluorophenyl)-5-(6-fluorochroman-2-yl)-4H-1,2,4-triazole-3-thiol (4j)

Yield 75%, mp 229–231°C; IR (DRS): 3061(Ar, C–H str.), 2951 (C–H str.), 2535(–SH str.), 1589(–C=C–, str.), 1462(H–C–H bend), 1520(C–O str.), 1075(C–F str.) cm−1; 1H NMR (400 MHz, CDCl3): δ ppm 2.34(s, 6H, 3CH, 3CH), 2.21–2.46(m, 2H, 2CH), 2.75–2.85(m, 2H, 2CH), 3.83(s, 3H, OCH3), 4.90–4.97(dd, J = 12.6 Hz, 6 Hz, 1H, CH), 6.72–6.95(m, 3H, ArH), 7.13–7.22(m, 3H, ArH), 13.05(s, 1H, SH). 13C NMR (100 MHz, CDCl3): 26.27(CH2), 28.87(CH2), 85.3(CH), 108.29(CH), 108.69(CH) 112.98(CH), 116.81(CH), 117.32(CH), 118.79(C), 127.11(CH), 129.2(C), 139.69 (C), 155.8(C), 158.29(C), 159.93(C), 173.54(C). MS: m/z = 363 [M]+; Anal. Calcd for C17H12F3N3O2S: C, 56.19; H, 3.33; N, 11.56. Found: C, 56.06; H, 3.14; N, 11.32%.

4.2. General Procedure for the Synthesis of Functionalized 4-Thiazolidinones 5a–5j

An equimolar mixture of 6-fluorochroman-2-carbohydrazide 2 (0.01 mol) and different aryl aldehydes (0.01 mol) was taken in RBF and to this, thioglycolic acid (mercaptoacetic acid) (0.29 mol) in toluene was added. Then reaction mixture was allowed to reflux in a Dean-Stark assembly with continuous stirring. After completion of the reaction (48 hrs monitoring by TLC), the content was cooled to room temperature and then neutralized with saturated sodium bicarbonate solution. The organic extracts were washed with water and dried over Na2SO4. The solvent was evaporated in vacuo and the resulting crude product was purified by column chromatography to give the analytical pure compounds 5a–5j. Column chromatography was carried out in hexane: ethyl acetate solvent system. Pure compound was eluted in 23% ethyl acetate in hexane.

4.2.1. 6-Fluoro-N-(2-(4-methoxyphenyl)-4-oxothiazolidine-3-yl) chroman-2-carboxamide (5a)

Yield 85%, mp 98–100°C; IR (DRS): 3383(Amide–NH str.), 3081(Ar, C–H str.), 2958(C–H str.), 1714(C=O str.), 1688(amide C=O str.), 1542(–NH bend), 1365(C–F str.), 1278(C–O–C str.) cm−1; 1H NMR (400 MHz, DMSO-d6): δ ppm 2.15–2.40(m, 2H, 2CH), 2.75–2.85(m, 2H, 2CH), 3.83(s, 3H, OCH3), 4.69–4.72(d, J = 16.0 Hz, 1H, CH), 3.91–3.95(d, J = 15.6 Hz, 1H, CH), 4.69–4.72(dd, J = 3.6 Hz, 3.2 Hz, 1H, CH), 5.92(s, 1H, CH), 6.72–6.95(m, 3H, ArH), 6.87–7.84(m, 4H, ArH), 8.0(s, 1H, NH), 13C NMR (100 MHz, DMSO-d6): δ ppm 25.25(CH2), 26.19(CH2), 34.2(CH2), 55.33(CH3), 70.50(CH), 85.58(CH), 108.7(CH), 112.44(CH), 114.1(CH), 116.43(CH), 126.91(CH), 129.9(C), 133.68(C), 154.35(C), 157.18 (C), 155.8(C), 158.08(C), 165.35(C), 169.36(C). MS: m/z = 402 [M]+; Anal. Calcd for C20H19FN2O4S: C, 59.69; H, 4.76; N, 6.96. Found: C, 59.23; H, 4.61; N, 6.88%.

4.2.2. 6-Fluoro-N-(2-(2-nitrophenyl)-4-oxothiazolidine-3-yl) chroman-2-carboxamide (5b)

Yield 95%, mp 190–192°C; IR (DRS): 3392(Amide–NH str.), 3205(Ar, C–H str.), 1712(C=O str.), 1678(amide C=O str.), 1523(–NH bend), 1590(N=O str.), 1259(C–O–C str.), 1190(C–F str.) cm−1; 1H NMR (400 MHz, DMSO-d6): δ ppm 1.81–2.05(m, 2H, 2CH), 2.61–2.74(m, 2H, 2CH), 3.68–3.72(d, J = 16.0 Hz, 1H, CH), 3.91–3.95(d, J = 15.6 Hz, 1H, CH), 4.66–4.69(dd, J = 3.6 Hz, 3.2 Hz, 1H, CH), 6.12(s, 1H, CH), 6.72–6.79(m, 1H, ArH), 6.84–6.91(m, 2H, ArH), 7.60–7.63(t, 1H, ArH), 7.78–7.87(m, 2H, ArH), 8.04–8.06(d, J = 8.0 Hz, 1H, ArH), 10.43–10.46(d, J = 11.6 Hz, 1H, NH). 13C NMR (100 MHz, DMSO-d6): δ ppm 25.25(CH2), 26.19(CH2), 34.2(CH2), 68.3(CH), 85.58(CH), 108.7(CH), 114.1(CH), 116.43(CH), 123.91(CH), 125.5(C), 129.87(CH), 129.9(C), 127.85(CH), 132.06(C), 149.87(C), 154.35(C), 157.18 (C), 169.36(C). MS: m/z = 417 [M]+; Anal. Calcd for C19H16FN3O5S: C, 54.67; H, 3.86; N, 10.07. Found: C, 54.58; H, 3.49; N, 9.99%.

4.2.3. 6-Fluoro-N-(2-(4-fluorophenyl)-4-oxothiazolidine-3-yl) chroman-2-carboxamide (5c)

Yield 89%, mp 106–110°C; IR (DRS): 3487(Amide–NH str.), 3041(Ar, C–H str.), 1710(C=O str.), 1676(amide C=O str.), 1537(–NH bend), 1201(C–O–C str.), 1190(C–F str.) cm−1; 1H NMR (400 MHz, CDCl3): δ ppm 1.82–2.02(m, 2H, 2CH), 2.56–2.70(m, 2H, 2CH), 3.59–3.78(m, 2H, 2CH), 4.45–4.58(dd, J = 10.52 Hz, 11.52 Hz, 1H, CH), 5.79–5.83(d, J = 17.32 Hz, 1H, CH), 6.54–6.72(m, 3H, ArH), 6.86–6.90(t, 1H, ArH), 6.99–7.03(t, 1H, ArH), 7.20–7.22(t, 1H, ArH), 7.33–7.36(t, 1H, ArH), 8.05–8.13(d, J = 29.44 Hz, 1H, NH). 13C NMR (100 MHz, CDCl3): δ ppm 25.25(CH2), 26.19(CH2), 34.2(CH2), 70.52(CH), 85.58(CH), 108.7(CH), 113.27(CH), 114.1(CH), 116.43(CH), 127.64(CH), 129.9(C), 136.68(C), 154.35(C), 157.18 (C), 160.07(C), 165.35(C), 169.36(C). MS: m/z = 390 [M]+; Anal. Calcd for C19H16F2N2O3S: C, 58.45; H, 4.13; N, 7.18. Found: C, 58.02; H, 4.03; N, 7.10%.

4.2.4. N-(2-(3-Chlorophenyl)-4-oxothiazolidine-3-yl)-6-fluorochroman-2-carboxamide (5d)

Yield 77%, mp 151–153°C; IR (DRS): 3401(Amide–NH str.), 3200(Ar, C–H str.), 1717(C=O str.), 1645(amide C=O str.), 1550(–NH bend), 1245(C–F str.), 1201(C–O–C str.), 820(C–Cl str.) cm−1; 1H NMR (400 MHz, DMSO): δ ppm 2.15–2.40(m, 2H, 2CH), 2.75–2.85(m, 2H, 2CH), 4.66–4.69(d, J = 16.0 Hz, 1H, CH), 3.91–3.95(d, J = 15.6 Hz, 1H, CH), 4.69–4.72(dd, J = 3.6 Hz, 3.2 Hz, 1H, CH), 5.92(s, 1H, CH), 6.72–6.95(m, 3H, ArH), 7.24–7.43(m, 4H, ArH), 8.0(s, 1H, NH). 13C NMR (100 MHz, CDCl3): δ ppm 25.25(CH2), 26.19(CH2), 34.2(CH2), 71.78(CH), 85.58(CH), 108.7(CH), 114.1(CH), 116.43(CH), 124.5(CH), 124.93(CH), 126.41(CH), 128(CH), 132.25(C), 140.45(C), 145.35(C), 157.18 (C), 165.35(C), 169.36(C). MS: m/z = 406 [M]+; Anal. Calcd for C19H16ClFN2O3S: C, 56.09; H, 3.96; N, 6.89. Found: C, 55.90; H, 3.83; N, 6.83%.

4.2.5. N-(2-(4-Bromophenyl)-4-oxothiazolidine-3-yl)-6-fluorochroman-2-carboxamide (5e)

Yield 90%, mp 118–120°C; IR (DRS): 3452(Amide–NH str.), 3000(Ar, C–H str.), 1725(C=O str.), 1640(amide C=O str.), 1545(–NH bend), 1345(C–F str.), 1251(C–O–C str.), 520(C–Br str.) cm−1; 1H NMR (400 MHz, DMSO-d6): δ ppm 2.15–2.40(m, 2H, 2CH), 2.75–2.85(m, 2H, 2CH), 4.63–4.66(d, J = 16.0 Hz, 1H, CH), 3.91–3.95(d, J = 15.6 Hz, 1H, CH), 4.63–4.66(dd, J = 3.6 Hz, 3.2 Hz, 1H, CH), 5.92(s, 1H, CH), 6.72–6.95(m, 3H, ArH), 7.12–7.85(m, 4H, ArH), 8.0(s, 1H, NH). 13C NMR (100 MHz, DMSO-d6): δ ppm 25.25(CH2), 26.19(CH2), 34.2(CH2), 70.50(CH), 85.58(CH), 108.7(CH), 114.1(CH), 116.43(CH), 120.41(C), 126.7(CH), 129.36(CH), 129.9(C), 138.93(C), 154.35(C), 157.18 (C), 165.35(C), 169.36(C). MS: m/z = 452 [M+1]+; Anal. Calcd for C19H16BrFN2O3S: C, 50.56; H, 3.57; N, 6.21. Found: C, 50.45; H, 3.28; N, 6.11%.

4.2.6. 6-Fluoro-N-(2-(4-hydroxyphenyl)-4-oxothiazolidine-3-yl) chroman-2-carboxamide (5f)

Yield 73%, mp 132–134°C; IR (DRS): 3452(Amide–NH str.), (–OH, broad), 3011(Ar, C–H str.), 1728(C=O str.), 1645(amide C=O str.), 1545(–NH bend), 1352(C–F str.), 1278(C–O–C str.) cm−1; 1H NMR (400 MHz, DMSO-d6): δ ppm 2.15–2.40(m, 2H, 2CH), 2.75–2.85(m, 2H, 2CH), 4.63–4.66(d, J = 16.0 Hz, 1H, CH), 3.91–3.95(d, J = 15.6 Hz, 1H, CH), 4.63–4.66(dd, J = 3.6 Hz, 3.2 Hz, 1H, CH), 5.35(s, 1H, OH), 5.92(s, 1H, CH), 6.72–6.95(m, 3H, ArH), 7.14–7.86(m, 4H, ArH), 8.0(s, 1H, NH). 13C NMR (100 MHz, DMSO-d6): δ ppm 25.25(CH2), 26.19(CH2), 34.2(CH2), 55.33(CH3), 70.50(CH), 85.58(CH), 108.7(CH), 114.1(CH), 116.43(CH), 116.68(C), 125.81(CH), 129.9(C), 132.68(C), 154.35(C), 157.46 (C), 157.18(C), 165.35(C), 169.36(C). MS: m/z = 388 [M]+; Anal. Calcd for C19H17FN2O4S: C, 58.75; H, 4.41; N, 7.21. Found: C, 58.56; H, 4.34; N, 7.06%.

4.2.7. 6-Fluoro-N-(4-oxo-2-(p-tolyl) thiazolidin-3-yl) chroman-2-carboxamide (5g)

Yield 84%, mp 89–91°C; IR (DRS): 3328(Amide–NH str.), 2998(Ar, C–H str.), 2900(C–H str.), 1741(C=O str.), 1652(amide C=O str.), 1548(–NH bend), 1371(C–F str.), 1300(C–O–C str.) cm−1; 1H NMR (400 MHz, DMSO-d6): δ ppm 2.15–2.32(m, 2H, 2CH), 2.34(s, 3H, 3CH), 2.75–2.85(m, 2H, 2CH), 4.63–4.66(d, J = 16.0 Hz, 1H, CH), 3.91–3.95(d, J = 15.6 Hz, 1H, CH), 4.63–4.66(dd, J = 3.6 Hz, 3.2 Hz, 1H, CH), 5.92(s, 1H, CH), 6.72–6.95(m, 3H, ArH), 7.11(m, 4H, ArH), 8.0(s, 1H, NH). 13C NMR (100 MHz, DMSO-d6): δ ppm 21.03(CH3), 25.25(CH2), 26.19(CH2), 34.2(CH2), 70.50(CH), 85.58(CH), 108.7(CH), 114.1(CH), 116.43(CH), 126.73(CH), 127.98(CH), 129.9(C), 136.48(C), 136.52(C), 154.35(C), 157.18(C), 165.35(C), 169.36(C). MS: m/z = 386 [M]+; Anal. Calcd C20H19FN2O3S: C, 62.16; H, 4.96; N, 7.25. Found: C, 62.07; H, 4.55; N, 7.09%.

4.2.8. N-(2-(2-Chlorophenyl)-4-oxothiazolidine-3-yl)-6-fluorochroman-2-carboxamide (5h)

Yield 71%, mp 158–160°C; IR (DRS): 3412(Amide–NH str.), 3212(Ar, C–H str.), 1725(C=O str.), 1685(amide C=O str.), 1558(–NH bend), 1251(C–F str.), 1228(C–O–C str.), 800(C–Cl str.), 770(o-di substituted) cm−1; 1H NMR (400 MHz, DMSO): δ ppm 2.15–2.32(m, 2H, 2CH), 2.75–2.85(m, 2H, 2CH), 4.63–4.66(d, J = 16.0 Hz, 1H, CH), 3.91–3.95(d, J = 15.6 Hz, 1H, CH), 4.63–4.66(dd, J = 3.6 Hz, 3.2 Hz, 1H, CH), 5.92(s, 1H, CH), 6.72–6.95(m, 3H, ArH), 7.17–7.65(m, 4H, ArH), 8.0(s, 1H, NH). 13C NMR (100 MHz, CDCl3): δ ppm 25.25(CH2), 26.19(CH2), 34.2(CH2), 67.50(CH), 85.58(CH), 108.7(CH), 114.1(CH), 116.43(CH), 125.18(CH), 125.89(CH), 127.02(CH), 127.26(CH), 129.9(C), 131.68(C), 133.39(C), 154.35(C), 157.18 (C), 165.35(C), 169.36(C). MS: m/z = 406 [M]+; Anal. Calcd for C19H16ClFN2O3S: C, 56.09; H, 3.96; N, 6.89. Found: C, 55.93; H, 3.77; N, 6.84%.

4.2.9. 6-Fluoro-N-(2-(4-nitrophenyl)-4-oxothiazolidine-3-yl) chroman-2-carboxamide (5i)

Yield 79%, mp 207–209°C; IR (DRS): 3398(Amide–NH str.), 3212(Ar, C–H str.), 1728(C=O str.), 1688(amide C=O str.), 1543(–NH bend), 1595(N=O str.), 1272(C–O–C str.), 1290(C–F str.) 790(p-di substituted) cm−1; 1H NMR (400 MHz, CDCl3): δ ppm 2.15–2.32(m, 2H, 2CH), 2.75–2.85(m, 2H, 2CH), 4.63–4.66(d, J = 16.0 Hz, 1H, CH), 3.91–3.95(d, J = 15.6 Hz, 1H, CH), 4.63–4.66(dd, J = 3.6 Hz, 3.2 Hz, 1H, CH), 5.92(s, 1H, CH), 6.72–6.95(m, 3H, ArH), 7.49–8.14(m, 4H, ArH), 8.0(s, 1H, NH). 13C NMR (100 MHz, CDCl3): δ ppm 25.25(CH2), 26.19(CH2), 34.2(CH2), 70.52(CH), 85.58(CH), 108.7(CH), 114.1(CH), 116.43(CH), 122.91(CH), 126.32(CH), 129.9(C), 144.08(C), 145.35(C), 154.35 (C), 157.18(C), 165.35(C), 169.36(C). MS: m/z = 417 [M]+; Anal. Calcd for C17H14FN3O2: C, 54.67; H, 3.86; N, 10.07. Found: C, 54.39; H, 3.79; N, 9.89%.

4.2.10. N-(2-(3-Bromophenyl)-4-oxothiazolidine-3-yl)-6-fluorochroman-2-carboxamide (5j)

Yield 88%, mp 166–168°C; IR (DRS): 3482(Amide–NH str.), 3110(Ar, C–H str.), 1745(C=O str.), 1590(amide C=O str.), 1485(–NH bend), 1354(C–F str.), 1281(C–O–C str.), 680(m-di substituted), 520(C–Br str.) cm−1; 1H NMR (400 MHz, CDCl3): δ ppm 2.15–2.32(m, 2H, 2CH), 2.75–2.85(m, 2H, 2CH), 4.63–4.66(d, J = 16.0 Hz, 1H, CH), 3.91–3.95(d, J = 15.6 Hz, 1H, CH), 4.63–4.66(dd, J = 3.6 Hz, 3.2 Hz, 1H, CH), 5.92(s, 1H, CH), 6.72–6.95(m, 3H, ArH), 7.22–7.41(m, 4H, ArH), 8.0(s, 1H, NH). 13C NMR (100 MHz, CDCl3): δ ppm 25.25(CH2), 26.19(CH2), 34.2(CH2), 70.32(CH), 85.58(CH), 108.7(CH), 114.1(CH), 116.43(CH), 120.91(C), 127.55(CH), 127.95(CH), 128.17(CH), 128.74(CH), 129.9(C), 140.65(C), 154.35(C), 157.18 (C), 165.35(C), 169.36(C).MS: m/z = 452 [M+1] +; Anal. Calcd for C19H16FN3O5S: C, 50.56; H, 3.57; N, 6.21. Found: C, 50.17; H, 3.14; N, 6.12%.

Acknowledgments

The authors are thankful to the department of chemistry for providing laboratory facilities. The authors are thankful for facilities and grants given under UGC-SAP for Department Research Support (DRS) and Department of Science and Technology (DST) New Delhi for Fund for Improvement of Science and Technology (FIST). The authors are also thankful to RSIC Chandigarh for providing 1H NMR and 13C NMR spectral analysis of the compounds.

Conflict of Interests

The authors do not have a direct financial relation with the commercial identity mentioned in the paper that might lead to a conflict of interests for any of the authors.

References

1. Kers I., Csjernyik G., MacSari I., et al. Structure and activity relationship in the (S)-N-chroman-3-ylcarboxamide series of voltage-gated sodium channel blockers. Bioorganic and Medicinal Chemistry Letters. 2012;22(17):5618–5624. doi: 10.1016/j.bmcl.2012.06.105. [PubMed] [Cross Ref]
2. Nishida T., Yoshinaga H., Toyoda T., Toshima M. First- and second-generation practical syntheses of chroman-4-one derivative: a key intermediate for the preparation of SERT/5-HT1A dual inhibitors. Organic Process Research and Development. 2012;16(4):625–634. doi: 10.1021/op200357h. [Cross Ref]
3. Mauler F., Horváth E. Neuroprotective efficacy of repinotan HCl, a 5-HT1A receptor agonist, in animal models of stroke and traumatic brain injury. Journal of Cerebral Blood Flow and Metabolism. 2005;25(4):451–459. doi: 10.1038/sj.jcbfm.9600038. [PubMed] [Cross Ref]
4. Ross S. B., Thorberg S., Jerning E., et al. Robalzotan (NAD-299), a novel selective 5-HT(1A) receptor antagonist. CNS Drug Reviews. 1999;5(3):213–232.
5. Cleophas T. J., Grabowsky I., Niemeyer M. G., Mäkel W. N., van der Wall E. E. Long-term efficacy of nebivolol monotherapy in patients with hypertension. Current Therapeutic Research—Clinical and Experimental. 2001;62(6):451–461. doi: 10.1016/S0011-393X(01)80056-4. [Cross Ref]
6. Shelke S., Mhaske G., Gadakh S., Gill C. Green synthesis and biological evaluation of some novel azoles as antimicrobial agents. Bioorganic & Medicinal Chemistry Letters. 2010;20(24):7200–7204. doi: 10.1016/j.bmcl.2010.10.111. [PubMed] [Cross Ref]
7. Sztanke K., Tuzimski T., Rzymowska J., Pasternak K., Kandefer-Szerszeń M. Synthesis, determination of the lipophilicity, anticancer and antimicrobial properties of some fused 1,2,4-triazole derivatives. European Journal of Medicinal Chemistry. 2008;43(2):404–419. doi: 10.1016/j.ejmech.2007.03.033. [PubMed] [Cross Ref]
8. Alanine A., Anselm L., Steward L., Thomi S., Vifian W., Groaning M. D. Synthesis and SAR evaluation of 1,2,4-triazoles as A2A receptor antagonists. Bioorganic and Medicinal Chemistry Letters. 2004;14(3):817–821. doi: 10.1016/j.bmcl.2003.09.095. [PubMed] [Cross Ref]
9. Zamani K., Faghihi K., Sangi M. R., Zolgharnein J. Synthesis of some new substituted 1,2,4-triazole and 1,3,4-thiadiazole and their derivatives. Turkish Journal of Chemistry. 2003;27(1):119–125.
10. Raghav N., Singh M. Acyl hydrazides and triazoles as novel inhibitors of mammali an cathepsin B and cathepsin H. European Journal of Medicinal Chemistry. 2014;77:231–242. doi: 10.1016/j.ejmech.2014.03.007. [PubMed] [Cross Ref]
11. Singh S. P., Parmar S. S., Raman K., Stenberg V. I. Chemistry and biological activity of thiazolidinones. Chemical Reviews. 1981;81(2):175–203. doi: 10.1021/cr00042a003. [Cross Ref]
12. Kavitha C. V., Basappa, Swamy S. N., et al. Synthesis of new bioactive venlafaxine analogs: Novel thiazolidin-4-ones as antimicrobials. Bioorganic and Medicinal Chemistry. 2006;14(7):2290–2299. doi: 10.1016/j.bmc.2005.11.017. [PubMed] [Cross Ref]
13. Kumar A., Sharma S., Bajaj K., et al. Some new 2,3,6-trisubstituted quinazolinones as potent anti-inflammatory, analgesic and COX-II inhibitors. Bioorganic and Medicinal Chemistry. 2003;11(23):5293–5299. doi: 10.1016/S0968-0896(03)00501-7. [PubMed] [Cross Ref]
14. Sharma S., Singh T., Mittal R., Saxena K. K., Srivastava V. K., Kumar A. A study of anti-inflammatory activity of some novel α-amino naphthalene and β-amino naphthalene derivatives. Archiv der Pharmazie. 2006;339(3):145–152. doi: 10.1002/ardp.200500215. [PubMed] [Cross Ref]
15. Raja Solomon V., Haq W., Srivastava K., Puri S. K., Katti S. B. Synthesis and antimalarial activity of side chain modified 4-aminoquinoline derivatives. Journal of Medicinal Chemistry. 2007;50(2):394–398. doi: 10.1021/jm061002i. [PubMed] [Cross Ref]
16. Zhou H., Wu S., Zhai S., et al. Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. Journal of Medicinal Chemistry. 2008;51(5):1242–1251. doi: 10.1021/jm7012024. [PubMed] [Cross Ref]
17. Pathak R. B., Chovatia P. T., Parekh H. H. Synthesis, antitubercular and antimicrobial evaluation of 3-(4-chlorophenyl)-4-substituted pyrazole derivatives. Bioorganic and Medicinal Chemistry Letters. 2012;22(15):5129–5133. doi: 10.1016/j.bmcl.2012.05.063. [PubMed] [Cross Ref]
18. Barreca M. L., Balzarini J., Chimirri A., et al. Design, synthesis, structure - Activity relationships, and molecular modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agents. Journal of Medicinal Chemistry. 2002;45(24):5410–5413. doi: 10.1021/jm020977+. [PubMed] [Cross Ref]
19. Harisha R. S., Hosamani K. M., Keri R. S. Synthesis, in-vitro microbial and cytotoxic studies of new benzimidazole derivatives. Archiv der Pharmazie. 2009;342(7):412–419. doi: 10.1002/ardp.200900022. [PubMed] [Cross Ref]
20. Cunico W., Gomes C. R. B., Ferreira M. D. L. G., Capri L. R., Soares M., Wardell S. M. S. V. One-pot synthesis of 2-isopropyl-3-benzyl-1,3-thiazolidin-4-ones and 2-phenyl-3-isobutyl-1,3-thiazolidin-4-ones from valine, arenealdehydes and mercaptoacetic acid. Tetrahedron Letters. 2007;48(35):6217–6220. doi: 10.1016/j.tetlet.2007.06.101. [Cross Ref]
21. St. Laurent D. R., Gao Q., Wu D., Serrano-Wu M. H. Regioselective synthesis of 3-(heteroaryl)-iminothiazolidin-4-ones. Tetrahedron Letters. 2004;45(9):1907–1910. doi: 10.1016/j.tetlet.2004.01.001. [Cross Ref]

Articles from International Scholarly Research Notices are provided here courtesy of Hindawi